ARDX · Ardelyx, Inc.
$4.06
+0.15 (+3.84%)
At close · Aug 14
Market Cap
$1.01B
Shares
249.19M
Ardelyx, Inc. Earnings Call Transcripts
Every quarterly earnings call for Ardelyx, Inc. (ARDX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲325.1%
$4.99M
−$22.89M
'22 Q3
22-11-03
▲4193.3%
$44.18M
$10.70M
'22 Q4
23-03-02
▲2329.3%
$11.37M
−$26.77M
'23 Q1
23-05-03
▲784.1%
$22.33M
−$17.12M
'23 Q2
23-08-02
▲1031%
$56.39M
$6.63M
'23 Q3
23-10-31
▼22.2%
$34.36M
−$28.80M
'23 Q4
24-02-22
▲304.8%
$46.02M
−$26.52M
'24 Q1
24-05-02
▲227.9%
$73.22M
−$16.45M
'24 Q2
24-08-01
▲74.2%
$98.24M
−$809,000
'24 Q3
24-10-31
▲237.9%
$116.13M
$4.64M
'24 Q4
25-02-20
▲61%
$74.11M
−$41.14M
'25 Q1
25-05-01
▲33.4%
$97.66M
−$19.08M
'25 Q2
25-08-04
▲12.3%
$110.33M
−$969,000
'25 Q3
25-10-30
▲7.8%
$125.22M
−$407,000
'25 Q4
26-02-19
▲27.5%
$94.47M
−$37.60M
'26 Q1
26-04-30
LATEST
▲23.8%
$120.88M
−$16.72M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Ardelyx Q2 2026 Earnings
Positive tone
Exposa (XPHOZA) growth and market opportunity
Ibsrela payer access hurdles and new patient starts
Revenue growth and Q2 record results
Revenue
$120.88M
▲ 23.8% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference in New York
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Ardelyx, Inc. Q1 FY2026 Earnings Call
Revenue
$94.47M
▲ 27.5% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Ardelyx, Inc. Q4 FY2025 Earnings Call
Confident tone
Pipeline expansion and development programs
EXPOSA patient access strategy
Long-term growth guidance and outlook
Revenue
$125.22M*
▲ 7.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Ardelyx, Inc. Q3 FY2025 Earnings Call
Confident tone
IBSRELA commercial momentum
XPHOZAH commercial performance
Pipeline development with ARDX-10531
Revenue
$110.33M
▲ 12.3% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-04
Ardelyx, Inc. Q2 FY2025 Earnings Call
Confident tone
Deliberate withholding of XPHOZAH guidance
Raised IBSRELA full-year guidance
XPHOZAH market dynamics and growth
Revenue
$97.66M
▲ 33.4% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Ardelyx, Inc. Q1 FY2025 Earnings Call
Confident tone
IBSRELA commercial performance
XPHOZAH commercial performance
XPHOZAH long-term opportunity
Revenue
$74.11M
▲ 61% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Ardelyx, Inc. Q4 FY2024 Earnings Call
Confident tone
$750 million XPHOZAH growth ambition
XPHOZAH launch and CMS coverage change
IBSRELA commercial momentum
Revenue
$116.13M*
▲ 237.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Ardelyx, Inc. Q3 FY2024 Earnings Call
Positive tone
XPHOZAH launch momentum
IBSRELA growth and field force expansion
Medicare reimbursement/CMS bundle risk
Revenue
$98.24M
▲ 74.2% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ardelyx, Inc. Q2 FY2024 Earnings Call
Confident tone
XPHOZAH launch momentum
IBSRELA commercial growth
CMS bundle / oral-only policy risk
Revenue
$73.22M
▲ 227.9% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Ardelyx, Inc. Q1 FY2024 Earnings Call
Confident tone
XPHOZAH launch performance
IBSRELA commercial growth
Phosphate management unmet need
Revenue
$46.02M
▲ 304.8% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Ardelyx, Inc. Q4 FY2023 Earnings Call
Confident tone
XPHOZAH launch and uptake
IBSRELA commercial momentum
Payer access and prior authorization
Revenue
$34.36M*
▼ 22.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Ardelyx, Inc. Q3 FY2023 Earnings Call
Revenue
$56.39M
▲ 1031% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Ardelyx, Inc. Q2 FY2023 Earnings Call
Revenue
$22.33M
▲ 784.1% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Ardelyx, Inc. Q1 FY2023 Earnings Call
Revenue
$11.37M
▲ 2329.3% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Ardelyx, Inc. Q4 FY2022 Earnings Call
Revenue
$44.18M*
▲ 4193.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Ardelyx, Inc. Q3 FY2022 Earnings Call
Revenue
$4.99M
▲ 325.1% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ardelyx, Inc. Q2 FY2022 Earnings Call
Revenue
$2.53M
▲ 92.4% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ardelyx, Inc. Q1 FY2022 Earnings Call
Revenue
$468,000
▼ 92.9% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Ardelyx, Inc. Q4 FY2021 Earnings Call
Revenue
$1.03M*
▼ 43.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–20 of 20 earnings calls
Key facts
CIK
1437402
CUSIP
039697107
13F (30d)
243 filings
237 filers
Visit website
Investor relations